Видео ютуба по тегу Trial: Icaria-Mm

ICARIA-MM Phase III Trial Overview
ICARIA-MM Phase III Trial Overview
Update on the ICARIA-MM trial
Update on the ICARIA-MM trial
Dr. Lonial on the ICARIA-MM Trial in Heavily Pretreated Multiple Myeloma
Dr. Lonial on the ICARIA-MM Trial in Heavily Pretreated Multiple Myeloma
ICARIA-MM: final OS analysis
ICARIA-MM: final OS analysis
ASCO 2019: Isatuximab ICARIA-MM Trial Updates with Dr. Paul Richardson
ASCO 2019: Isatuximab ICARIA-MM Trial Updates with Dr. Paul Richardson
Updates from ICARIA-MM, a phase 3 study of Isa + pomalidomide & low-dose dex (Pd) versus Pd in RRMM
Updates from ICARIA-MM, a phase 3 study of Isa + pomalidomide & low-dose dex (Pd) versus Pd in RRMM
ICARIA-MM
ICARIA-MM
ICARIA MM: efficacy and safety of isatuximab, pomalidomide and dexamethasone in patients with RRMM
ICARIA MM: efficacy and safety of isatuximab, pomalidomide and dexamethasone in patients with RRMM
Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study
Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study
Isatuximab Plus Pomalidomide/Low-Dose Dex Vs Pomalidomide/Low-Dose Dex in Pts with RRMM (ICARIA-MM)
Isatuximab Plus Pomalidomide/Low-Dose Dex Vs Pomalidomide/Low-Dose Dex in Pts with RRMM (ICARIA-MM)
Saad Usmani: BELLINI, CANDOR, ICARIA-MM and CAR-T
Saad Usmani: BELLINI, CANDOR, ICARIA-MM and CAR-T
MOA and Safety Profile of Isatuximab from the ICARIA Study
MOA and Safety Profile of Isatuximab from the ICARIA Study
Isatuximab phase 3 study in patients with relapsed and refractory multiple myeloma
Isatuximab phase 3 study in patients with relapsed and refractory multiple myeloma
IKEMA trial update: Isatuximab in MM
IKEMA trial update: Isatuximab in MM
The safety and efficacy of isatuximab for R/R myeloma: insights from ICARIA-MM, IKEMA & CANDOR
The safety and efficacy of isatuximab for R/R myeloma: insights from ICARIA-MM, IKEMA & CANDOR
Updates from ICARIA-MM: longer-term efficacy data on the combination of Isa-Pd in R/R myeloma
Updates from ICARIA-MM: longer-term efficacy data on the combination of Isa-Pd in R/R myeloma
ICARIA-MM: isatuximab, pomalidomide & dexamethasone
ICARIA-MM: isatuximab, pomalidomide & dexamethasone
Parameswaran Hari, MD, MRCP, offers his impression of the Phase 3 ICARIA-MM trial from ASH 2019
Parameswaran Hari, MD, MRCP, offers his impression of the Phase 3 ICARIA-MM trial from ASH 2019
Isatuximab: a ‘next-generation monoclonal antibody’
Isatuximab: a ‘next-generation monoclonal antibody’
ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone
ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone
What is isatuximab? And how does it compare with daratumumab?
What is isatuximab? And how does it compare with daratumumab?
Москва падет, москвичей будут лечить шоковой терапией. Беседа с Катей Марголис.
Москва падет, москвичей будут лечить шоковой терапией. Беседа с Катей Марголис.
ICARIA study: Isatuximab and pom/dex for multiple myeloma
ICARIA study: Isatuximab and pom/dex for multiple myeloma